Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lacteol fort for Antipsychotic-Induced Weight Gain
NCT06936137Phase 3Recruiting
- Sponsor
- Ain Shams University
- Start
- Apr 2025
- Primary completion
- Jun 2026
- Modality
- Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Lactobacillus LB in antipsychotic-induced weight gain (AIWG), sponsored by Ain Shams University. Primary endpoint: Weight change from baseline at 12 weeks. Started Apr 2025; status: recruiting.
02
Drugs
Lactobacillus LB
03
Conditions
antipsychotic-induced weight gain (AIWG)
Beyond the preview
Go deeper on NCT06936137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06936137.